Peter Fasolo - Johnson Johnson President

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>JJ</div>
JNJ -- USA Stock  

Fiscal Quarter End: 30th of June 2020  

  President
Dr. Peter M. Fasolo Ph.D. is Chief Human Resource Officer, Executive Vice President of the Company. Dr. Fasolo joined the Company in 2004 as Vice President, Worldwide Human Resources for Cordis Corporationrationration, a subsidiary of the Company, and was subsequently named Vice President, Global Talent Management for the Company. He left Johnson Johnson in 2007 to join Kohlberg Kravis Roberts Co. as Chief Talent Officer. Dr. Fasolo returned to the Company in 2010 as the Vice President, Global Human Resources, and in 2011, he became a member of the Executive Committee. In April 2016, he was named Executive Vice President, Chief Human Resources Officer
Age: 56  President Since 2016      
732 214-0332  www.jnj.com
Fasolo has responsibility for global talent, recruiting, diversity, compensation, benefits, employee relations and all aspects of the human resources agenda for the Company.

Peter Fasolo Latest Insider Activity

Johnson Johnson Management Efficiency

Johnson Johnson has Return on Asset of 0.0092 % which means that on every $100 spent on asset it made $0.0092 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.0195 % implying that it generated $0.0195 on every 100 dollars invested. Johnson Johnson management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current Return on Investment is estimated to increase to 22.69, while Return on Average Assets are estimated to decrease to 0.0001. Johnson Johnson Asset Turnover is decreasing as compared to previous years. The last year's value of Asset Turnover was reported at 0.50. The current Tangible Assets Book Value per Share is estimated to increase to 30.39, while Goodwill and Intangible Assets are estimated to decrease to under 75.9 B. The current Tax Liabilities is estimated to increase to about 20.2 B, while Total Liabilities is estimated to decrease to under 90.3 B.
The company has 30.43 B in debt with debt to equity (D/E) ratio of 50.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Johnson Johnson has Current Ratio of 1.3 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Andre WyssNovartis AG
2016
Joseph CaldarellaBristol Myers Squibb
2010
William LeeGilead Sciences
2015
Frank ClyburnMerck Company
2019
Stephen FryEli Lilly And
2011
Enrique ConternoEli Lilly And
2017
John McHutchisonGilead Sciences
2018
Darren CarrollEli Lilly And
2015
Ann JudgeBristol Myers Squibb
2016
Barton PetersonEli Lilly And
2009
Adam SchechterMerck Company
2010
Lafmin MorganGrifols S A
N/A
Paul CarterGilead Sciences
2014
Melissa BarnesEli Lilly And
2013
Murdo GordonBristol Myers Squibb
2016
Robert DavisMerck Company
2016
Nick HironsGlaxoSmithKline PLC
2014
Menelas PangalosAstrazeneca PLC
2019
Jeffrey SimmonsEli Lilly And
2008
Daniel SkovronskyEli Lilly And
2018
Paul AutenriedBristol Myers Squibb
2016

Company Summary

Johnson Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. The company was founded in 1886 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 132200 people.Johnson Johnson (JNJ) is traded on BATS Exchange in USA. It is located in One Johnson and Johnson Plaza, New Brunswick, NJ 08933, United States and employs 132,200 people. Johnson Johnson is listed under Pharmaceutical Products category by Fama And French industry classification.

Johnson Johnson Leadership Team

A Washington, Independent Director
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee
William Perez, Independent Director
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Marillyn Hewson, Independent Director
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer
Mary Coleman, Independent Director
Michael Ullmann, VP, General Counsel and Member of Executive Committee
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Mary Beckerle, Independent Director
Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee
Scott Davis, Director
Louise Mehrotra, Vice President Investor Relations
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Ronald Williams, Independent Director
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
D Davis, Independent Director
Hubert Joly, Independent Director
Anne Mulcahy, Lead Independent Director
Joseph Wolk, Chief Financial Officer, Executive Vice President
Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer
Ian Davis, Independent Director
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee
Mark McClellan, Independent Director
Charles Prince, Independent Director
Eugene Washington, Independent Director
Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee
Peter Fasolo, Chief Human Resource Officer, Executive Vice President
Susan Lindquist, Independent Director
Mark Weinberger, Independent Director

Stock Performance Indicators

Current Sentiment - JNJ

Johnson Johnson Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Johnson Johnson. What is your judgment towards investing in Johnson Johnson? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Please also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page